Literature DB >> 28456572

Treatment with sodium nitroprusside improves the endothelial function in aortic rings with endothelial dysfunction.

Tereza Cristina Buzinari1, Jorge Camargo Oishi1, Thiago Francisco De Moraes1, Izabela Pereira Vatanabe1, Heloisa Sobreiro Selistre-de-Araújo1, Cezar Rangel Pestana2, Gerson Jhonatan Rodrigues3.   

Abstract

PURPOSE: Verify if sodium nitroprusside (SNP) is able to improve endothelial function and if this effect is independent of nitric oxide (NO) release of the compound.
METHODS: Normotensive (2K) and hypertensive (2K-1C) wistar rats were used. Intact endothelium aortas were placed in a myograph and incubated with SNP: 0.1nM; 1nM or 10nM during 30min. Cumulative concentration-effect curves for acetylcholine (Ach) were realized to measure the relaxing capacity. Intracellular NO were measured (by DAF-2DA probe) in HUVEC treated with SNP 0.1nM or DETA/NO 0.1μM. The detection of intracellular superoxide radical (O2•-) was obtained by using DHE probe.
RESULTS: Treatment of 2K-1C aortic rings with SNP (0.1; 1.0 and 10nM) improved endothelium dependent relaxation induced by acetylcholine. This improvement induced by SNP was verified at the concentration of 0.1nM, which does not release NO, suggesting that this effect was not induced due to NO release by SNP compound. Besides, we show that the cell treatment with 0.1nM of SNP decreased the fluorescence intensity to DHE in cells stimulated with angiotensin II. These results indicate that SNP decreases the concentration of O2•- in HUVEC cells.
CONCLUSIONS: The SNP at a concentration that does not release NO inside the cells is able to attenuate endothelial dysfunction. DRUGS AND CHEMICALS: Acetylcholine (Ach) (PubChem CID:6060); angiotensin II human (Ang II) (PubChem CID: 16211177); diethylenetriamine/nitric oxide (DETA-NO) (PubChem CID 4518); dihydroethidium (DHE) (PubChem CID: 128682); phenylephrine (Phe) (PubChem CID: 5284443); sodium nitroprusside (SNP) (PubChem CID: 11963579); Thiazolyl Blue Tetrazolium Bromide (MTT) (PubChem CID: 64965); 4,5-diaminofluorescein diacetate (DAF-2DA); 4-hidroxy-Tempo (Tempol) (PubChem CID: 137994), were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Endothelial dysfunction; Nitric oxide; Sodium nitroprusside; Superoxide

Mesh:

Substances:

Year:  2017        PMID: 28456572     DOI: 10.1016/j.ejps.2017.04.022

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  4 in total

Review 1.  The role of nitric oxide in renovascular hypertension: from the pathophysiology to the treatment.

Authors:  Bruna Pinheiro Pereira; Gabriel Tavares do Vale; Carla Speroni Ceron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-07       Impact factor: 3.000

2.  A divergent mode of activation of a nitrosyl iron complex with unusual antiangiogenic activity.

Authors:  Edinilton Muniz Carvalho; Lisa A Ridnour; Florêncio Sousa Gouveia Júnior; Pedro Henrique Bezerra Cabral; Nilberto Robson Falcão do Nascimento; David A Wink; Douglas W Franco; Mayara Jane Campos de Medeiros; Daniel de Lima Pontes; Elisane Longhinotti; Tércio de Freitas Paulo; Vania Bernardes-Génisson; Remi Chauvin; Eduardo Henrique Silva Sousa; Luiz Gonzaga de França Lopes
Journal:  J Inorg Biochem       Date:  2020-06-20       Impact factor: 4.155

3.  Leonurine Attenuates Obesity-Related Vascular Dysfunction and Inflammation.

Authors:  Xiao-Dong Shi; Jia-Xin Zhang; Xi-De Hu; Tao Zhuang; Ning Lu; Cheng-Chao Ruan
Journal:  Antioxidants (Basel)       Date:  2022-07-08

4.  In vitro sepsis induces Nociceptin/Orphanin FQ receptor (NOP) expression in primary human vascular endothelial but not smooth muscle cells.

Authors:  Mark F Bird; Barbara Gallacher-Horley; John McDonald; David G McVey; Fatin Al-Janabi; Remo Guerrini; Girolamo Calo; Shu Ye; Jonathan P Thompson; David G Lambert
Journal:  PLoS One       Date:  2022-09-15       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.